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Methods and matrices: approaches to identifying
miRNAs for Nasopharyngeal carcinoma
Jordan L Plieskatt1,2†, Gabriel Rinaldi1,2,3†, Yanjung Feng1,2, Paul H Levine4, Samantha Easley5, Elizabeth Martinez5,
Salman Hashmi4, Nader Sadeghi6, Paul J Brindley1,2, Jeffrey M Bethony1,2* and Jason P Mulvenna7

Abstract
Background: Nasopharyngeal carcinoma (NPC) is a solid tumor of the head and neck. Multimodal therapy is highly
effective when NPC is detected early. However, due to the location of the tumor and the absence of clinical signs,
early detection is difficult, making a biomarker for the early detection of NPC a priority. The dysregulation of small
non-coding RNAs (miRNAs) during carcinogenesis is the focus of much current biomarker research. Herein, we
examine several miRNA discovery methods using two sample matrices to identify circulating miRNAs (c-miRNAs)
associated with NPC.
Methods: We tested two miRNA discovery workflows on two sample sources for miRNAs associated with NPC. In
the first workflow, we assumed that NPC tumor tissue would be enriched for miRNAs, so we compared miRNA
expression in FFPE from NPC cases and controls using microarray and RNA-Seq technologies. Candidate miRNAs
from both technologies were verified by qPCR in FFPE and sera from an independent NPC sample set. In a second
workflow, we directly interrogated NPC case and control sera by RNA-Seq for c-miRNAs associated with NPC, with
candidate c-miRNAs verified by qPCR in the sera from the same independent NPC sample set.
Results: Both microarray and RNA-Seq narrowed the miRNA signature to 1-5% of the known mature human
miRNAs. Moreover, these two methods produced similar results when applied to the same sample type (FFPE), with
RNA-Seq additionally indicating “unknown” miRNAs associated with NPC. However, we found different miRNA
profiles in NPC sera compared to FFPE using RNA-Seq, with the few overlapping miRNAs found to be significantly
up-regulated in FFPE significantly down-regulated in sera (and vice versa). Despite the different miRNA profiles
found in FFPE and sera, both profiles strongly associated with NPC, providing two potential sources for biomarker
signatures for NPC.
Conclusions: We determined that the direct interrogation of sera by RNA-Seq was the most informative method
for identifying a c-miRNA signature associated with NPC. We also showed that there are different miRNA expression
profiles associated with NPC for tumor tissue and sera. These results reflect on the methods and meaning of miRNA
biomarkers for NPC in tissue and peripheral blood.
Keywords: Nasopharyngeal carcinoma, Methods, Biomarker, MicroRNAs, qPCR, Next generation sequencing,
RNA-Seq, Tumor
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Background
Nasopharyngeal carcinoma (NPC) is an Epstein Barr virus
(EBV) associated squamous cell carcinoma of the head
and neck. While notable for its distinct geographical distribution [1,2], this solid tumor is also remarkable for its
extensive interaction with the tumor microenvironment
and the host immune system (e.g., immunoediting) [3].
Peripheral blood and saliva collected from NPC patients
often contains numerous tumor-derived products, including cytokines [4,5], non-cytokine tumor proteins [4,6-10],
and viral nucleic acids, as well as EBV antibodies and antigens [3,11-15]. These circulating tumor and oncogenic
viral products represent an easily accessible source for
biomarkers and make NPC, as Gourzones et al. [3] state, a
“privileged model” for peripheral blood biomarkers.
In this manuscript, we focus on methods that could
be used to identify circulating miRNA (c-miRNAs) biomarkers. These small non-coding RNAs are key players
in post-transcriptional expression regulation and are
involved in a wide range of cellular processes, often
circulating as long-range signaling molecules in the
peripheral blood [16-20]. Numerous miRNAs have
been found in nearly all sample matrices associated
with cancer, including tumor tissue, sera, plasma, and
saliva. Moreover, it has been demonstrated that miRNA
levels are “stable, reproducible, and consistent among individuals with the same cancer” [21], and are being used
as biomarkers for breast [22], colorectal [23] and ovarian
cancers [24]. When compared to other biomarker species,
miRNAs offer unique advantages: (1) they can be amplified using qPCR, enabling their levels to be verified and
quantified with a high degree of sensitivity and specificity
in serum or plasma; (2) multiple miRNAs can be amplified

by multiplex qPCR, which (3) enables the simultaneous
detection of dysregulated miRNAs (miRNA signatures)
within the same sample. In addition, high quality small
RNA preparations, enriched with miRNAs, can be extracted from formalin-fixed paraffin embedded (FFPE) tissue [25-28], the clinical standard for the processing NPC
tumor samples, enabling us to utilize our extensive repository of NPC biospecimens from around the world [29-34].
Herein, we assess two methods (microarray and RNASeq) for miRNA expression profiling applied to two different sample types (FFPE and sera) from NPC cases and age,
sex, and geographically matched controls. While sera
presents the richest and most easily accessible source
for circulating miRNA biomarkers, the dynamic range
and low abundance of most biomarker species in sera
makes it a challenging matrix for initial miRNA biomarker
discovery. As with other studies of solid tumor biomarkers
[20,35,36], our workflow assumed that abundant miRNAs
from the primary tumor enter into the bloodstream, where
they can be utilized as biomarkers, as shown for breast,
lung and prostate cancers [37,38]. Accordingly, we assessed
two methods for miRNA biomarker discovery based on
sample type and discovery platform (Figure 1). In the first
biomarker discovery workflow, we started with the interrogation of FFPE from confirmed NPC cases versus matched
healthy controls using “targeted” and an “untargeted” discovery platforms, i.e., microarray versus RNA-Seq, respectively. Subsequently, a set of candidate miRNAs associated
with NPC was verified using qPCR for their detection
and quantitation in sera. This method was based on the
assumption that NPC, more than any other solid tumor,
has an extensive interaction with the host, especially the
host immune system (i.e., “immunoediting”) and tumor

miRNA Discovery MATRIX 1

miRNA Discovery MATRIX 2

Tissue Discovery Set
(case vs. control)

Serum Discovery Set
(case vs. control)

Microarray

Small RNA-seq

(miRBase r.16)

(miRBase r.19 + “novel”)

qPCR
Serum Verification Set
(case vs. control)

Small RNA-seq

EBV Serology

(miRBase r.19 + “novel”)
miRNA Verification

Figure 1 Flow diagram of methods and matrices explored for discovering a circulating miRNA signature for nasopharyngeal carcinoma
in a training set of samples. Both targeted, (microarray) and an untargeted (small RNA-Seq) approaches were used to determine relative expression levels of miRNA in FFPE NPC tumor tissue compared to normal control tissue (black arrows). Based on this analysis, qPCR was used to confirm miRNA expression levels in tissue and to target these miRNAs in sera (colored thick arrows). qPCR results showed miRNA expression levels in
sera had little correlation with tissue RNA-Seq used to profile expression levels in this same sample matrix. Cognate serology support verification
and correlation of detected miRNAs (red arrow).

Sample

Histologic type

WHO classification1

TNM2

Sex

Age

Ethnicity

Origin

Non-keratinizing

T4N2M0

M

46

Asian

USA

History at presentation

Tumor FFPE
Tumor 1

Differentiated

Right sphenoid mass; Right neck mass; bloody nasal discharge; facial numbness; headache

Tumor 2

Differentiated

Non-keratinizing

T3N0M0

F

80

Hispanic

USA

Right sphenoid mass; Right neck mass; bloody nasal discharge; facial numbness; headache

Tumor 3

Undifferentiated

Non-keratinizing

T4N2M0

M

47

Asian

USA

Large mass involving posterior wall of nasopharynx with superior extension and inferior
involvement right oropharyngeal wall

Tumor 4

Undifferentiated

Non-keratinizing

T3N1M0

M

49

NA

USA

Right sided 3 cm neck mass; hypermetabolic activity in right nasopharynx on PET/CT
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Table 1 Describes the formalin fixed paraffin embedded (FFPE) tissue from biopsies of histologically confirmed nasopharyngeal carcinoma tissue and two
corresponding controls from non-tumor tissue and two biopsies of patients with nasal polyposis from the Department of Pathology, George Washington
University, DC, USA

Control FFPE
Control 1

Non-neoplastic tissue adjacent to Tumor 1

Control 2

Non-neoplastic tissue adjacent to Tumor 2

Asian

USA

Sinonasal mucosa adjacent to NPC tumor

Hispanic

USA

Sinonasal mucosa adjacent to NPC tumor

Control 3

–

–

–

F

43

African-American

USA

Nasal polyposis with chronic rhinosinusitis; large nasopharyngeal mass

Control 4

–

–

–

M

65

NA

USA

Nasal polyposis with chronic rhinosinusitis; large nasopharyngeal mass

FFPE are presented by histological type, WHO classification [40], TNM staging [39], sex, age, ethnicity, origin of FFPE, and the history at presentation. Currently, the WHO divides NPC into keratinizing, non-keratinizing,
and basaloid squamous cell carcinoma. Non-keratinizing NPC, which is the most common form of NPC, is further subdivided into differentiated and undifferentiated.
1
[40]; 2[39]; NA indicates that data were not available.
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micro-environment [3]. In the second biomarker discovery
workflow, we directly interrogated NPC case and control
sera by RNA-Seq for circulating miRNAs (c-miRNAs)
associated with NPC, with candidate c-miRNAs verified in
serum by qPCR. While most studies of miRNA expression
in cancer have focused on biomarker discovery in either
tumor tissue or sera/plasma, this study is among the first
to compare the different methods and matrices for biomarker discovery for NPC.

Methods
Sample characteristics and preparation
Case and control tissue preparation

Detailed characteristics of the FFPE samples used in
this study are shown in Tables 1 and 2. In brief, formalin fixed paraffin-embedded tissue blocks from four
cases of histologically confirmed non-keratinizing undifferentiated NPC (the most common form of NPC)
diagnosed between 2004 and 2012 and four samples of
non-neoplastic nasorespiratory tissue were obtained
from the biological repository at the Department of
Pathology, The George Washington University Hospital,
Washington, DC. Tissue specimens were fixed in 10%
neutral buffered formalin and processed into paraffin wax
(FFPE) by routine methods. Two of the control samples
were non-neoplastic sinusoidal mucosal tissue biopsied
from ipsilateral sites distal to the primary tumor (at an
undetermined distance) at the time of the original diagnostic procedure. The other control tissues were chronic
allergic sinusitis, chronic rhinosinusitis, sinus mucosa
with chronic inflammation, and sinus mucosa with no

significant histologic abnormality. All tissue sections were
reviewed independently by two pathologists (E.M. and
S.E.E.) to confirm the histopathologic diagnosis and to
classify tumors by World Health Organization (WHO)
terminology [35]. The age, sex, ethnicity, Tumor Node
and Stage (TNM) [39], and WHO classification of
nasopharyngeal [40] tumors are described in detail in
Table 1. The cases included three men and one woman
between 46 and 80 years of age. One master re-cut
hematoxylin and eosin (H&E) stained slide was made for
samples. For the NPC cases, paraffin blocks containing >90% viable tumor were selected for dissection. Two
FFPE samples of non-keratinizing differentiated and two
of non-keratinizing undifferentiated NPC as well as 8
non-neoplastic control samples (8 samples) underwent
RNA isolation and microarray analysis as described
below. Due to limited tissue area and recovered RNA,
RNA sequencing was performed on only three of the four
tumor samples (Tumor 2 omitted) and only two of the
four non-neoplastic nasorespiratory tissue samples. Representative images of NPC cases and non-neoplastic controls are shown in Additional file 1.
Case and control sera

Detailed characteristics of the serum samples used in this
study are shown in Table 2 and in manuscripts [29-34].
In brief, serum samples for this study consisted of anonymously coded vials of sera from histopathologically
confirmed cases of nasopharyngeal carcinoma (NPC) and
their corresponding healthy controls from studies undertaken by the National Cancer Institute (NCI), National

Table 2 Shows the serum samples for this study consists of anonymously coded vials of sera from histopathologically
confirmed cases of nasopharyngeal carcinoma (NPC) and their corresponding healthy controls from studies
undertaken by the National Cancer Institute, National Institutes of health, USA and detailed in manuscripts 30, 31, 32,
and 40
Origin1

Sample
N

M

F

Mean (95% CI)

Germany4

Case2

10

10

0

Control

6

5

1

Case

5

3

Control

3

2

Case

12

12

0

49.5 (44.9, 54.1)

Non-keratinizing

Control

4

4

0

50.0 (39.6, 60.4)

Healthy

USA5
Malaysia6

Total

Sex

Age

WHO [40]
classification

Subtype

Ethnicity

Ref

60.5 (50.7, 70.3)

Non-keratinizing

Differentiated

Caucasian

[31]

NA3

Healthy

2

60.0 (48.9, 71.2)

Non-keratinizing

1

61.0 (41.2, 80.8)

Healthy

Caucasian
Differentiated

Caucasian

[32]

Caucasian
Undifferentiated

Asian

[29,41]

Asian

Case

27

25

2

52.1 (47.8, 56.3)

–

–

–

Control

13

11

2

53.7 (43.8, 64.1)

–

–

–

The samples were maintained under Good Biobanking Practices at the Biorepositories and Biospecimen Research Branch (BBRB), National Cancer Institute,
Frederick, MD, National Institutes of Health, USA.
1
All specimens biobanked and received from the Biorepositories and Biospecimen Research Branch (BBRB), National Cancer Institute, National Institute of
Health, USA.
2
The term “case” refers to histologically confirmed nasopharyngeal carcinoma.
3
NA indicates an absence of data for this group.
4
Ear Nose and Throat Clinic, Cologne University, Germany.
5
North American NPC Study, Mayo Clinic, USA.
6
Institute of Radiotherapy, Oncology and Nuclear Medicine at the General Hospital, Kuala Lumpur, Malaysia.

–
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Institutes of Health (NIH), USA, as part of a multicenter
studies involving institutions in the USA, Germany, and
Malaysia [29-31,33,34] and maintained and shipped from
the Biorepositories and Biospecimen Research Branch
(BBRB), of the NCI-NIH, Frederick, MD, USA. As a part of
these NCI studies, sera were matched for age, ethnicity,
sex, and country of residence with sera from healthy
controls. For this study, 16 serum samples were from a
Malaysian collection, which were shipped from a treatment
facility in Kuala Lumpur, Malaysia to the National Cancer
Institute, Bethesda, MD [32]. Twenty-four samples were
from a multicenter study that included samples from ENT
Clinic at Cologne University, Germany [31], and from the
Massachusetts Eye and Ear Infirmary at the Massachusetts
General Hospital in Boston [29]. All sera were from patients who underwent complete clinical investigation to determine TNM status (see manuscripts).
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ACL, without carrier RNA and buffer ATL was then
added and the sample was pulse-vortexed for 30 seconds before incubation at 60°C for 30 min. Buffer ACB
and isopropanol (Acros) were added to the sample and
incubated for 5 minutes on ice. The samples were applied to the QIAamp Mini column using the QIAvac 24
Plus. The columns were washed with buffer ACW1,
ACW2 and ethanol, dried at 56°C for 5 minutes and
miRNAs eluted in 50 μL Buffer AVE. Concentration,
purity and integrity (RIN) for the RNA were determined by spectrophotometry (Nanodrop 1000) and
Agilent 2100 Bioanalyzer using the Agilent RNA 6000
Nano, pico, and Small RNA kits as appropriate. RNAs
were stored at < −50°C.
Microarray analysis

The GWU IRB determined that the study samples used
in this study did not meet the definition of human subjects research; i.e., a living individual about whom an investigator conducting research obtains: a) data through
intervention or interaction with the individual or b) private identifiable information. This determination was
made since the samples were limited to preexisting, deidentified specimen analysis labeled with a random code
(see attached PDF).

Total RNA (250 μg) isolated from each FFPE case was
labeled with Cyanine 3-pCp using Agilent miRNA labeling and hybridization kits, hybridized to the Agilent
human miRNA microarray (miRBase Release 16.0), and
scanned. The feature intensities were transferred to digital
data and Log2 transformed using Feature Extraction
(V.10.7). For data analysis, inter-sample variance was
normalized using quantile normalization strategies.
Hierarchical clustering by Euclidean distance was used
to cluster samples and groups with similar miRNA
profiles. Differential analysis was performed using an
unpaired t-test, ANOVA, and fold-change analysis.

Isolation of RNA
FFPE

Small RNA sequencing
Rio-Zero pretreatment of total RNA from FFPE

Total RNA was isolated from FFPE sections using the
miRNeasy FFPE kit (Qiagen) according to manufacturer’s protocol. Briefly, 320 μL Deparaffinization Solution (Qiagen) was added followed by brief vortexing,
centrifugation and incubation for 3 minutes at 56°C.
Buffer PKD was added to the samples before centrifugation and proteinase K treatment at 56°C for 15 minutes.
The samples were then incubated at 80°C for 15 minutes
to partially reverse formaldehyde modification. The
lower phase was then transferred to a new tube and
DNase digestion was performed at room temperature
for 15 minutes. 500 μL RBC buffer and 100% ethanol
(Acros Chemical) were added to the samples and transferred to the RNeasy MiniElute column. The column
was washed twice with RPE, and RNA eluted in 30 μL
RNase-free water.

RNA purified from FFPE were depleted of rRNA by treatment with the Ribo-Zero rRNA Removal Kit (Cat. No.
RZH1086, Epicentre), as described by the manufacturer.
Briefly, biotinylated capture probes directed against rRNA
sequences were added to total RNA samples and allowed
to hybridize. Biotinylated complexes were removed using
streptavidin-conjugated microbeads and non-ribosomal
RNAs precipitated in ethanol.

Ethical approval

Sera

miRNAs were isolated from sera using the QIAamp
Circulating Nucleic Acid Kit (Qiagen) according to the
manufacturer’s protocol for purification of circulating
miRNAs from serum, plasma or urine. Up to 0.5 mL of
serum was digested with 400 μL proteinase K. Buffer

Library preparation and sequencing

Libraries were prepared for small RNA sequencing using
the TruSeq Small RNA Sample Prep Kit (Illumina). Illumina libraries were constructed from 1,000 ng of total
RNA. Briefly, indexed oligonucleotide adapters were ligated
to both the 3′-hydroxyl end and the 5′-phosphate end of
the miRNAs using T4 RNA Ligase (New England Biolabs).
RNA was reverse-transcribed and amplified using 14 cycles
of PCR with primers targeting the 5′ and 3′ adapters, a
specific index sequence, and Illumina sequencing adapters.
The resulting products were analyzed and quantified using
Agilent 2100 BioAnalyzer and the molar amount of mature
miRNA present in the library was estimated by integrating
the area under the curve in the 145 – 160 bp range.
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Individual libraries were mixed to create multiplexed pools,
the mixture was gel purified, and the 145–160 bp range of
RNA excised from the gel, crushed using a Gel Breaker
tube (IST Engineering), eluted with nuclease-free water,
and precipitated in ethanol. The concentration of the final
library pool was determined using the PicoGreen system
(Invitrogen) and the size distribution of the pool by the Agilent 2100 BioAnalyzer. Library pools were normalized to 2
nM for sequencing. Sequencing was performed using an
Illumina Genome Analyzer IIx. Library preparation and
small RNA sequencing was performed by Expression Analysis, A Quintiles Company (Durham, NC).
Micro-RNA alignment, mapping and annotation

Adapter sequences were clipped from deep sequencing
reads using FastqMcf (http://code.google.com/p/ea-utils/
wiki/FastqMcf ) and initial quality assessment performed
using FastQC (http://www.bioinformatics.babraham.ac.
uk/projects/fastqc/). To analyze miRNA expression profiles both miRDeep 2.0.0.5 [42] and miRExpress 2.0 [43]
were used. Briefly, short reads were mapped to the
human (UCSC hg19) and the Human herpes virus
4 (Epstein-Barr virus) genome (NCBI NC_007605.1)
allowing a minimum read length of 18, zero mismatches
in the seed region and a maximum of five genomic loci.
Known human and EBV miRNAs were identified and
quantified based on miRBase Release 19 [44] entries.
Using miRExpress known human and EBV miRNAs
were identified from miRBase Release 19 with an alignment identity of 1% a tolerance range of four and a
similarity threshold of 0.8 in the analysis. Differential
expression analysis was performed separately for miRDeep and miRExpress using a negative binomial distribution in EdgeR [45]. Only miRNAs with at least one
count per million in at least two samples were used in
expression analysis and counts were normalized using
the trimmed mean of M-values normalization method
[46]. The analysis was performed using moderated tagwise dispersions. Differentially expressed miRNAs were
defined as having a Benjamini and Hochberg corrected
p value of ≤ 0.05.
Quantitative real time PCR (qPCR)

cDNA was generated from 32–125 ng RNA using the miScript RT II kit (Qiagen) and the qPCR was performed using
the miScript SYBR Green PCR Kit (Qiagen) on custom
printed 96 well miScript miRNA arrays (SABiosciences).
Selected miRNAs and normalization controls printed on
the plate are shown in Additional file 2. The qPCRs were
performed using a BioRad iCycler iQ5 with an initial activation step of 95°C for 15 minutes followed by 40 cycles of
3-step cycling (denaturation, 15 sec, 94°C; annealing,
30 sec, 55°C; and extension, 30 sec, 70°C) followed by a
melting curve analysis for 81 cycles at 55°C and 20
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sec dwell time. Ct values were exported and analyzed
using SABiosciences tool (http://pcrdataanalysis.sabiosciences.com/mirna) and relative quantitation was performed using the ΔΔCt method [47]. SNORD and RT
controls were utilized for normalization of samples.
Database accession

RNA sequence data have been submitted to the Sequence
Read Archive (SRA, National Center for Biotechnology
Information, U.S. National Library of Medicine, Bethesda,
MD) under accession number SRP029599. Microarray
data were prepared according to MIAME standards and
deposited in the GEO (Gene Expression Omnibus Database, National Center for Biotechnology Information, U.S.
National Library of Medicine, Bethesda, MD) under accession number GSE46172.

Results
FFPE tissue yielded RNA of sufficient quality for
downstream analysis

Using the Qiagen miRNeasy FFPE kit, starting material of
2 × 10 μm sections provided RNA yields of ~100 ng/μm.
The purified RNA exhibited 260/280 and 260/230 ratios
of ~2.0 and ~1.9, respectively, which is considered an
acceptable level of purity for the downstream applications
in our program, including RNA-Seq. Both electrophoresis,
using TBE-urea gels, and analysis with the Agilent 2100
BioAnalyzer (not shown) were used to monitor RNA
profiles. Electropherograms of RNA isolated from FFPE
showed broad peaks at < 100 nt, which indicated that the
sample included small RNA species (not shown). The
integrity (or RIN score) of the samples ranged between
2–3. When taken with the absence of 28S and 18S ribosomal RNA peaks, this suggested the degradation of
larger RNA species. However, given the robustness of
miRNAs in FFPE tissue [48] and reports from other
groups [49] that RIN values have negligible effect on
miRNA results, the purified RNA was considered suitable for further analysis.
Microarray and RNA-Seq exhibited similar miRNAexpression profiles in FFPE tissue.
High-throughput analysis of miRNA expression profiles typically utilizes small RNA microarrays (i.e. targeted approach) or RNA-Seq (i.e., untargeted approach)
[20]. To compare the utility of the two techniques for
biomarker discovery, both approaches were used to profile miRNA expression in NPC FFPE tissue compared to
non-neoplastic nasorespiratory FFPE control tissue. For
microarray analysis, 250 ng purified RNA from eight
FFPE samples (four NPC FFPE and four non-neoplastic
nasorespiratory tissue FFPE) were analyzed using the
Agilent human miRNA microarray (miRBase Release 16.0),
which includes 1,205 human and 144 viral miRNA targets.
After hierarchical clustering and statistical analysis of
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differential expression, 31 miRNAs (13 down-regulated and
18 up-regulated) exhibited a fold change (FC) greater
than two (p < 0.05) in tumor tissue icompared to nonneoplastic nasorespiratory control tissue (Figure 2). Four
EBV miRNAs, (Bart4*, Bart5, Bart6-3p and Bart6-5p) were
significantly up-regulated in the four FFPE from the histologically confirmed NPC cases versus the non-neoplastic
nasorespiratory tissue controls. Absolute fold changes
along with p-values for all dysregulated miRNAs obtained
via microarray are shown in Additional file 3.
For RNA-Seq, one μg RNA from five FFPE tissue samples (3 NPC FFPE and 2 non-neoplastic nasorespiratory
tissue FFPE) was sequenced using the Illumina platform.
(Two non-neoplastic nasorespiratory tissue FFPE (Control
2 and Control 4) and one NPC FFPE (Tumor) were not
sequenced due to insufficient material0. Approximately 36
million reads were obtained across all FFPE samples and,

after quality filtering and short read removal, >32 million
reads were retained. The majority of reads (63%) mapped
to the human or EBV genomes, with miRNAs constituting
the predominant species of small RNAs identified
(Figure 3). Analyses with miRDeep and miRExpress provided expression data for 984 and 847 known human and
EBV miRNAs, respectively, each with greater than one
count per million in at least two of the samples. Using
EdgeR, 99 dysregulated miRNAs were identified in NPC
tumor tissue versus non-neoplastic nasorespiratory control samples (Table 3). Approximately one-third (37) of
these were of viral origin, all of which were up-regulated
in the NPC tumor samples (Table 3).
MicroRNA expression levels obtained in microarray
and RNA-Seq experiments were similar, with FC values
obtained from the two methods showing a positive association (Pearson correlation 0.43; Figure 4A). Eighty-

Tumor 3

Tumor 4

Tumor 11

Tumor 22

Control 4

Control 22

Control 3

Control 11

Figure 2 Hierarchical clustering of significantly changed miRNAs in NPC versus normal control tissue. Hierarchy heatmap generated using
a Euclidean distance metrics and centroid linkage method. Expression levels of each miRNA in each samples are represented by different colors
signifying hybridization intensities. Superscript numbering on sample names denotes those from the same individual (paired NPC/control tissue).
Further analysis with statistical information is presented in Additional file 3.
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20,000,000.0

Number of Reads

16,000,000.0

12,000,000.0

8,000,000.0

4,000,000.0
Sera

FFPE
0.0
micro RNA No annotation
small
Protein coding
nucleolar RNA

Other

RNA Class
Figure 3 Mapping of small RNA reads from FFPE and sera samples. Average reads and mapping per sample (total of five FFPE and four
sera). > 25 million reads were achieved for FFPE of which >16 million were miRNAs. ~ 12 million reads in total were sequenced from the sera, of
which ~ 6 million were mapped to miRNAs.

seven (87) human miRNA appeared to be dysregulated
using either discovery method technology, with only 11
found in both analyses. There were 32 and 44 miRNAs
identified independently by microarray and RNA-Seq,
respectively (Figure 4A). We observed a strong positive
correlation (Pearson correlation 0.85) between RNA-Seq
and microarray FC values for miRNAs found to be significantly dysregulated in microarray analysis, and a weaker
but still strong correlation for those identified as significantly dysregulated in the RNA-Seq analysis (Pearson
correlation 0.60) (Figure 4A). All but three miRNAs identified as significantly dysregulated in the microarray analysis
exhibited stronger up-regulation than in RNA-Seq, suggesting that cross-hybridization with closely related members
of miRNA families could have inflated their intensities
(Figure 4A). A similar effect, i.e. substantial differences
in called differentially expressed miRNAs despite overall similarity in FC values, was recently reported when
comparing the two platforms [56].
Optimized protocols for qPCR from minimal sera volumes

We evaluated three different RNA purification kits using
excess sera from healthy controls: the Qiagen miRNeasy,
Qiagen miRNeasy serum/plasma, and Qiagen QIAamp

Circulating Nucleic Acid kits. Using the manufacturers’
protocols, the Qiagen QIAamp kit was the most effective
of these kits with yields between 10–27 ng/μl serum compared to 0.5-1.0 ng RNA/μl from the other kits tested. This
provided at least 1 μg of total RNA from the volumes
available, typically ~0.25 ml, which is an amount adequate
for downstream applications such as RNA-Seq (≥1 μg total
RNA usually required). The purified RNA exhibited 260/
280 and 260/230 ratios of 1.6-1.9 and ~1.0, respectively.
Analysis of recovered RNA using the Agilent BioAnalyzer
2100 showed 28S and 18S ribosomal RNA bands. However, the enrichment of small RNA species lower than 100
nt in size was not observed (data not shown). As was the
case for FFPE samples, the RIN score (~3.0) suggested degradation of larger RNA species.
To verify miRNA expression levels in tumor tissue and
provide a tool for the measurement of miRNA levels in
sera, custom quantitative PCR (qPCR) plates were printed
with primers for 40 selected miRNAs found to be significantly dysregulated in the FFPE tissue by microarray
and RNA-Seq (Additional file 2). Given that only small
volumes of sera were available, a preliminary examination
of the effects of RNA concentration on qPCR was performed. Quantitative PCR experiments using both a small
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Table 3 Small RNA-Seq analysis of NPC FFPE tissue
Down-regulated
miRNA

MiRDeep (logFC)

MiRExpress (logFC)

Family

NPC ref.

hsa-let-7b-5p,hsa-let-7b

−1.23

−1.17

let-7/98/4458/4500

[36,50,51]

hsa-miR-100-5p,hsa-mir-100

−1.72

−1.57

miR-99ab/100

hsa-miR-1251,hsa-mir-1251

−5.69

−5.44

miR-1251

hsa-miR-1269a,hsa-mir-1269a

−6.44

-

miR-1269/1269b

-

hsa-miR-1269b,hsa-mir-1269b

−7.73

−6.14

miR-1269/1269b

-

[36,50,52-54]
-

hsa-miR-130a-3p,hsa-mir-130a

−2.82

−2.72

miR-130 ac/301ab/301b/301b-3p/454/721/4295/3666

hsa-miR-133a,hsa-mir-133a-1

−3.75

−3.63

miR-133abc

-

hsa-miR-133a,hsa-mir-133a-2

−3.75

−3.63

miR-133abc

-

hsa-miR-133b,hsa-mir-133b

−2.68

−2.74

miR-133abc

-

hsa-miR-136-5p,hsa-mir-136

−2.89

−2.77

miR-136

hsa-miR-139-5p,hsa-mir-139

−2.08

−2.04

miR-139-5p

hsa-miR-143-3p,hsa-mir-143

−1.64

−1.40

miR-143/1721/4770

hsa-miR-145-5p,hsa-mir-145

−2.77

−2.86

miR-145

hsa-miR-152,hsa-mir-152

−1.72

-

miR-148ab-3p/152

hsa-miR-187-3p,hsa-mir-187

−3.15

-

miR-187

[50,52,54]

[50,52,54]
[36,50,52,54]
[36]
[50,52]
[52]

hsa-miR-195-3p,hsa-mir-195

−2.37

−3.02

miR-15abc/16/16abc/195/322/424/497/1907

[50]

hsa-miR-195-5p,hsa-mir-195

−3.06

−2.29

miR-15abc/16/16abc/195/322/424/497/1907

[52]

hsa-miR-199a-5p,hsa-mir-199a-1

−2.46

−2.60

miR-199ab-5p

[55]

hsa-miR-199a-5p,hsa-mir-199a-2

−2.46

−2.60

miR-199ab-5p

[55]

-

−2.10

miR-199ab-5p

[52]

hsa-miR-204-5p,hsa-mir-204

−4.68

−4.62

miR-204/204b/211

[52]

hsa-miR-214-3p,hsa-mir-214

−2.79

−2.83

miR-214/761/3619-5p

-

hsa-miR-3065-5p,hsa-mir-3065

−3.73

−3.60

miR-545/3065/3065-5p

-

hsa-miR-335-5p,hsa-mir-335

−2.71

−2.68

miR-335/335-5p

-

hsa-miR-376a-5p,hsa-mir-376a-1

−3.96

−3.75

miR-376abd/376b-3p

-

hsa-miR-376b-5p,hsa-mir-376b

−3.45

-

miR-376abd/376b-3p

-

hsa-miR-376c-5p,hsa-mir-376c

−3.45

-

miR-376c/741-5p

-

hsa-miR-4423-5p,hsa-mir-4423

−6.24

−6.51

miR-4423-5p

-

-

−2.06

miR-450a/451a

-

hsa-mir-199b-5p,hsa-miR-199b

hsa-miR-450a-5p,hsa-mir-450a-1

-

−2.05

miR-450a/451a

-

hsa-miR-4792,hsa-mir-4792

−1.53

-

miR-4792

-

hsa-miR-488-3p,hsa-mir-488

−4.86

−4.46

miR-488

hsa-miR-497-3p,hsa-mir-497

−3.63

-

miR-15abc/16/16abc/195/322/424/497/1907

[50,52]

hsa-miR-497-5p,hsa-mir-497

−2.53

−2.46

miR-15abc/16/16abc/195/322/424/497/1907

[50,52]

hsa-miR-504,hsa-mir-504

−3.31

-

hsa-miR-539-5p,hsa-mir-539

−6.68

-

hsa-miR-542-3p,hsa-mir-542

−2.02

−1.96

hsa-miR-556-3p,hsa-mir-556

−5.18

-

miR-556-5p

-

hsa-miR-574-3p,hsa-mir-574

−1.32

−1.25

miR-574-3p

-

hsa-miR-585,hsa-mir-585

−2.51

-

miR-585

-

hsa-miR-874,hsa-mir-874

−1.68

−1.56

miR-874

-

hsa-miR-887,hsa-mir-887

−1.90

−1.99

miR-887

-

hsa-miR-891a,hsa-mir-891a

−7.14

−6.86

miR-891a

-

hsa-miR-450a-5p,hsa-mir-450a-2

miR-504/4725-5p

-

-

miR-300/381/539-3p

-

miR-542-3p

-
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Table 3 Small RNA-Seq analysis of NPC FFPE tissue (Continued)
Up-regulated
miRNA
hsa-mir-1268a,hsa-miR-1268a
hsa-mir-1268b,hsa-miR-1268b
hsa-miR-1303,hsa-mir-1303

MiRDeep (logFC)

MiRExpress (logFC)

-

2.89

Family
miR-1268/1268b

NPC ref.
-

-

2.59

miR-1268/1268b

-

1.61

1.62

miR-1303

-

hsa-miR-1304-3p,hsa-mir-1304

1.56

-

miR-1304

-

hsa-miR-1305,hsa-mir-1305

2.84

-

miR-1305

-

hsa-mir-15b-5p,hsa-miR-15b

-

1.09

miR-15abc/16/16abc/195/322/424/497/1907

hsa-miR-184,hsa-mir-184

4.84

5.22

miR-184

[52]

hsa-mir-21-3p,hsa-miR-21

-

1.41

miR-21/590-5p

-

hsa-mir-27a-3p,hsa-miR-27a

-

1.15

miR-27abc/27a-3p

-

hsa-miR-205-3p,hsa-mir-205

2.77

2.65

miR-205/205ab

[52]

hsa-miR-205-5p,hsa-mir-205

2.87

2.84

miR-205/205ab

[52]

hsa-miR-25-5p,hsa-mir-25

2.21

2.15

miR-25/32/92abc/363/363-3p/367

[52]

hsa-miR-4677-3p,hsa-mir-4677

1.52

1.74

miR-4677-3p

-

hsa-mir-4791,hsa-miR-4791

-

2.67

miR-3201/4791

-

hsa-mir-548n,hsa-miR-548n

-

3.79

miR-548abakhjiwy/548abcd-5p/559

-

-

hsa-miR-6510-3p,hsa-mir-6510

2.22

-

miR-6510-3p

-

hsa-miR-92a-3p,hsa-mir-92a-1

1.32

-

miR-25/32/92abc/363/363-3p/367

-

hsa-miR-92a-3p,hsa-mir-92a-2

1.28

-

miR-25/32/92abc/363/363-3p/367

-

-

1.47

miR-944

-

hsa-mir-944,hsa-miR-944

EBV specific (All up-regulated)
miRNA

MiRDeep (logFC)

MiRExpress (logFC)

ebv-miR-BART1-3p,ebv-mir-BART1

4.54

4.55

ebv-miR-BART1-5p,ebv-mir-BART1

4.37

4.37

ebv-miR-BART10-3p,ebv-mir-BART10

4.43

4.41

ebv-miR-BART10-5p,ebv-mir-BART10

4.24

4.49

ebv-miR-BART12,ebv-mir-BART12

3.52

3.47

ebv-miR-BART13-3p,ebv-mir-BART13

2.64

2.55

ebv-miR-BART13-5p,ebv-mir-BART13

4.29

4.32

ebv-miR-BART14-3p,ebv-mir-BART14

3.63

3.61

ebv-miR-BART14-5p,ebv-mir-BART14

3.78

3.83

ebv-miR-BART15,ebv-mir-BART15

3.70

3.68

ebv-miR-BART16,ebv-mir-BART16

3.52

3.53

ebv-miR-BART17-3p,ebv-mir-BART17

4.45

4.44

ebv-miR-BART17-5p,ebv-mir-BART17

4.81

4.72

ebv-miR-BART18-3p,ebv-mir-BART18

3.73

3.28

ebv-miR-BART18-5p,ebv-mir-BART18

4.44

4.44

ebv-miR-BART19-3p,ebv-mir-BART19

3.51

3.47

ebv-miR-BART19-5p,ebv-mir-BART19

4.58

-

ebv-miR-BART2-5p,ebv-mir-BART2

3.79

3.72

ebv-miR-BART20-3p,ebv-mir-BART20

3.41

3.39

ebv-miR-BART20-5p,ebv-mir-BART20

4.55

4.62

ebv-miR-BART21-3p,ebv-mir-BART21

2.79

2.71

ebv-miR-BART21-5p,ebv-mir-BART21

3.51

3.50
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Table 3 Small RNA-Seq analysis of NPC FFPE tissue (Continued)
ebv-miR-BART22,ebv-mir-BART22

3.97

3.93

ebv-miR-BART3-3p,ebv-mir-BART3

4.13

3.83

ebv-miR-BART3-5p,ebv-mir-BART3

4.66

4.50

ebv-miR-BART4-3p,ebv-mir-BART4

3.78

3.66

ebv-miR-BART4-5p,ebv-mir-BART4

3.37

3.32

ebv-miR-BART5-3p,ebv-mir-BART5

4.20

3.82

ebv-miR-BART5-5p,ebv-mir-BART5

3.97

3.89

ebv-miR-BART6-3p,ebv-mir-BART6

4.34

4.29

ebv-miR-BART6-5p,ebv-mir-BART6

4.49

4.35

ebv-miR-BART7-3p,ebv-mir-BART7

4.18

4.15

ebv-miR-BART7-5p,ebv-mir-BART7

5.77

5.76

ebv-miR-BART8-3p,ebv-mir-BART8

4.31

4.26

ebv-miR-BART8-5p,ebv-mir-BART8

4.65

4.63

ebv-miR-BART9-3p,ebv-mir-BART9

4.18

4.05

ebv-miR-BART9-5p,ebv-mir-BART9

4.47

4.45

Five FFPE samples previously analyzed by microarray were submitted for RNA-Seq and analyzed via both miRExpress and miRDeep tools. Significantly
dysregulated miRNAs are listed in Table 3.

quantity of total RNA (30 ng), and an amount recommended by the manufacturers (250 ng) were conducted
on RNA from both FFPE tissue and sera. A comparison of
the expression values obtained using both concentrations
revealed that, with one exception, no miRNAs displayed a
FC difference greater than two when using these starting
concentrations (Additional file 4). Given these results,
30 ng total RNA was used for subsequent experiments
and a threshold of greater than two-fold dysregulation, in
addition to significance value of p ≤ 0.05 was imposed
when determining significantly dysregulated miRNA expression levels via qPCR.
Expression levels determined using qPCR correlated with
microarray and RNA-Seq levels

Quantitative PCR was performed on RNA from tumor
and control tissue and expression levels showed good
agreement with results from the microarray and RNASeq analyses. Of the 40 miRNAs included on the
qPCR plate on the basis of their dysregulation in
tissue, all were identified using qPCR. Using linear
regression, ratios determined using RNA-Seq provided
better correlation with qPCR results (R2 0.65), while
a number of outliers reduced the overall correlation
of the microarray analysis with qPCR (R2 0.43)
(Figure 4B). Also evident were respective shifts of
+0.70 and +0.13 in the y-intercept of the linear regression line for microarray and RNA-Seq analysis
(Figure 4B). Shifts such as these have been observed
when comparing ratios from qPCR to microarray or
RNA-Seq ratios and they have been attributed to the

use of external references in the normalization of
qPCR results [56]. The use of external references for
normalization makes qPCR sensitive to miRNA
abundance when it varies between samples in relation to the external reference. For example, when
miRNA abundance, as a proportion of total RNA,
varies between samples and ribosomal RNA (which
makes up the majority of total RNA) is used as
the external reference. Microarray and RNA-Seq use
normalization methods internal to the miRNA population and are not susceptible to this effect. In this
analysis, SNORD was used to normalize qPCR results and thus positive shifts in the y-intercept could
reflect the presence of less miRNA in tumor compared with control tissue.
Expression levels of miRNAs found in FFPE were not
reflected in the sera

To quantify circulating miRNAs in NPC, 12 NPC positive sera were compared to sera from four healthy controls from a Malaysian sample set using qPCR. Test
samples were from age (+/− 10 years), and sex (male)
matched to the NPC patients, and each sample possessed associated serological analyses providing antiviral capsid antigen (VCA) IgG titers [34]. When these
samples were compared to healthy controls, only
three significantly dysregulated miRNAs were identified; miR-486-5p and miR-451 were up-regulated, and
miR-100 was down-regulated (fold change ≥ 2, p ≤ 0.05)
(not shown). All these miRNAs had been significantly
dysregulated in tumor tissue, using either RNA-Seq

Plieskatt et al. Journal of Translational Medicine 2014, 12:3
http://www.translational-medicine.com/content/12/1/3

Page 12 of 20

Figure 4 Comparison of RNA-Seq and microarray in the analysis of FFPE NPC tissue. A) The correlation of Fold Change (FC) values
calculated by RNA-Seq and microarray analysis on FFPE NPC and control tissue are shown. The left panel includes miRNAs detected using both
methods. The other panels show miRNAs identified as significantly dysregulated using both methods. Significantly dysregulated in only RNA-Seq
(Sign. Illumina) and those identified using only microarray analysis (Sign. Microarray) are also shown. Pearson coefficient for each analysis is shown
(PC). B) Comparison of FC values determined using qPCR and microarray analysis (first panel; Microarray) and qPCR and RNA-Seq (second panel;
Illumina). Best simple linear regression line is shown (solid line) and the R2, y-intercept and slope from are denoted on each graph; Y = X is shown
as a dotted line. Only miRNA’s included on the custom qPCR chip on the basis of their dysregulation in FFPE tissue using microarray analysis
and/or RNA-Seq are shown.

and/or microarray (Figure 2, Table 3). However, ratios
for miR-451 and miR-486-5p showed that expression
levels were inverted, indicating significant up-regulation
in sera, but down-regulation in tumor tissue. Based on
serology, the NPC cases were also analyzed as three individual groups: low (VCA IgG 40–160), medium (VCA
IgG 320–640), and high (VCA IgG >640) antibody titers.
In addition to miR-451, -486-5p, and −100, two additional
miRNAs were identified as significantly up-regulated in
the low titer group (miR-25 and let-7b) both of which
were also identified as significantly dysregulated in tumor
tissue, although let-7b had been identified as downregulated (Figure 5A). Finally, additional sera from the
U.S (five NPC sera and three matched healthy control

sera) and Germany (10 NPC sera and six healthy control
sera) were analyzed using the qPCR plates and the combined the results with those from the Malaysian sera.
When combined, only miR-486-5p was identified as significantly up-regulated (Figure 5A).
Despite the qPCR plates being designed using miRNAs found to be dysregulated in NPC tumor tissue,
few of these miRNAs were subsequently found in the
sera of NPC cases. Therefore, RNA-Seq was used as
an untargeted approach to profile the miRNAs in the
Malaysian sera discussed above. Sixteen (16) Malaysian
serum samples from individuals with histologically
confirmed NPC were pooled into four groups corresponding to low, medium and high levels of EBV VCA
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Figure 5 Quantitative PCR and RNA-Seq analysis of serum sample from NPC patients. Quantitative PCR was used to determine relative
expression levels for 40 miRNAs in 40 sera samples comprised of 14 control samples and 26 test cases; 16 sera from Malaysian patients, 16 from
German patients and eight from American patients (Malaysian, German, and American). A) Volcano plots of qPCR analysis of 40 sera samples. A
single miRNA (miR-486-5p) was found to be significantly up-regulated when samples were analyzed as a whole (panel one; All). An analysis of
Malaysian sera was also conducted incorporating anti-viral capsid antigen (VCA) IgG titers divided into four groups of four; a control group, low
VCA titer group (second panel; Malaysian (40–160)), a medium VCA titer group (third panel; Malaysian (320–640)) and a high VCA group (fourth
panel; Malaysian (> 640). Blue lines indicate a p-value of 0.05 and dashed lines show a four fold-change. Dysregulated miRNAs are shown in blue
and labeled with the human mature miRNA identification number. B) Heatmap of significantly dysregulated miRNAs from RNA-Seq analysis of
Malaysian sera. The heatmap was generated using the ‘heatmap.2′ function in the gplots R package and miRNA counts per million values were
scaled across samples and colored to represent up-regulation (1.0) and down-regulations (−1.0). C) Comparison of FC values, generated using
RNA-Seq, for miRNAs identified in FFPE and sera when compared to their respective controls. Left panel (All) shows comparison for all miRNAs
identified in both analyses and the right panel (Significant in Both) for miRNAs identified as dysregulated in both tissues. Three miRNAs were
identified as significantly up-regulated in sera but significantly down-regulated in FFPE tissue. Asterisk significant dysregulation in microarray analysis but not RNA-Seq. D) Comparison of FC values by qPCR and RNA-Seq in sera. Only miRNAs that were significantly dysregulated in RNA-Seq
and were present on the custom qPCR chip are shown.

titers
VCA
using
reads

as well as a control group with no detectable
(above). These four groups were then analyzed
the Illumina platform. Approximately 18 million
were obtained from the four groups, with 33% of

these reads (~5.7 million) mapped to miRNAs in miRBase (Figure 3). In total, 463 miRNAs were identified
in these sera. Of these miRNAs, 416 were also identified in the RNA-Seq analysis of the FFPE tissue.
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Differential analysis of serum miRNA counts using
EdgeR resulted in the identification of 20 miRNAs
that were significantly dysregulated in serum from
histologically confirmed NPC cases; 7 up-regulated
and 13 down-regulated (Figure 5B, Table 4). A comparison of the relative expression levels of miRNAs in
sera and FFPE showed little correlation (Pearson correlation 0.20; Figure 5C), indicating that the relative
expression of miRNAs in NPC FFPE tissue was not
reflected in sera from NPC cases. Six miRNAs that
had been previously identified as dysregulated in sera
using qPCR (above) were also identified using RNA-Seq
and three of these, let-7b, miR-451a and miR-486, were
shown to be significantly up-regulated in sera despite their significant down-regulation in tumor tissue
(Figure 5C). The other 14 significantly dysregulated sera
miRNAs had not been identified as dysregulated in tumors (Tables 3 and 4). Moreover, numerous miRNAs
strongly dysregulated in tumor samples were absent
from the sera (for example miR-205, miR-199a/b, and
miR-139) (Tables 3 and 4). FC values of the miRNAs
that were identified as significantly dysregulated in sera
by RNA-Seq and were also on the custom qPCR
plate used in analysis of sera showed similar values

(Figure 5D). Finally, despite the significant dysregulation
of 37 EBV miRNAs in tumor, no EBV miRNAs were
found to be significantly dysregulated in sera.
EBV miRNAs as potential NPC biomarkers

Both microarray and RNA-Seq analysis identified significant up-regulation of EBV miRNAs in tumor tissue.
Using RNA-Seq, 37 EBV miRNAs were identified as
significantly up-regulated and microarray analysis of
the same samples identified four up-regulated miRNAs
(ebv-miR-BART4*, ebv-miR-BART6-5p, ebv-miR-BART63p, ebv-miR-BART5). Though close association between
EBV and NPC suggests that EBV miRNAs could serve as
NPC biomarkers, no EBV miRNAs were found to be significantly dysregulated in serum by RNA-Seq. While the
average depth of RNA sequencing achieved on FFPE
samples was approximately 3.5 million reads, the average
depth for the serum samples was significantly lower at
~1.5 million. This difference may reflect the lower
amount of miRNA contained in sera and, therefore, low
abundance reads may not have been detected. To validate
this finding, qPCR was also used to assay EBV miRNAs
in sera. Nine (9) EBV specific primers were used to screen
40 total sera; 13 sera from healthy controls and 27 sera

Table 4 Small RNA-Seq analysis of sera of Malaysian cases
Down-regulated
miRNA

MiRDeep (logFC)

Family

hsa-let-7f-1

−1.75

let-7/98/4458/4500

hsa-let-7f-2

−1.80

let-7/98/4458/4500

hsa-miR-10a

−2.71

miR-10abc/10a-5p

hsa-miR-10b

−3.04

miR-10abc/10a-5p

hsa-miR-126-5p

−2.43

miR-126-5p

hsa-miR-148a-3p

−1.42

miR-148ab-3p/152

hsa-miR-151a-3p

−2.37

miR-151-5p/151b

hsa-miR-182-5p

−2.20

miR-182

hsa-miR-21-5p

−0.99

miR-21

hsa-miR-26a-1

−2.22

miR-26ab/1297/4465

hsa-miR-26a-2

−2.23

miR-26ab/1297/4465

hsa-miR-27b-3p

−2.06

miR-27abc/27a-3p

hsa-miR-584-5p

−1.93

miR-584

miRNA
hsa-let-7b

MiRDeep (logFC)
1.80

Family
let-7/98/4458/4500

hsa-miR-106b-3p

2.87

miR-17/17-5p/20ab/20b-5p/93/106ab/427/518a-3p/519d

hsa-miR-451a

3.33

miR-451

hsa-miR-484

2.17

miR-344a-5p/484/3155/3155b

hsa-miR-486-5p

3.06

miR-486-5p/3107

hsa-miR-92a-1

1.91

miR-25/32/92abc/363/363-3p/36

hsa-miR-92a-2

1.88

miR-25/32/92abc/363/363-3p/36

Serum pools generated from individual samples used in qPCR analysis from were also subjected to small RNA-Seq. Table 4 shows the dysregulated miRNAs
determined by the next generation sequencing.
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from NPC cases from three geographic locations (U.S.,
Germany, and Malaysia). While EBV miRNAs were
detected in all sera, no miRNAs were significantly dysregulated when case sera were compared to control
sera by qPCR. This is likely the result of the extensive
variation observed in sera for these miRNAs (Figure 6).
When the Malaysian sera were analyzed by VCA IgG
titers strata (as described above), ebv-BART-15 was
found to be significantly up-regulated in the mid-VCA
(VCA IgG 320–640 titre) (FC = 3.51, p = 0.04) and EbvBART-7* in the high VCA sample (VCA IgG >640 titre)
(FC = 1, p = <0.001) (Figure 7). Moreover, there appeared
to be an inverse correlation between serology (VCA IgG)
and EBV miRNA levels (Figure 7), i.e. the lowest NPC
VCA titer group (IgG 40–160) displayed the highest
positive FC in EBV miRNAs (FC 8–491) and the highest
VCA titer group (>1280) showed the lowest FC (0.39-1.02)
(values < 1.0 considered a negative FC). Overall, EBV levels
showed great variability, even within sera collected
from a single sample population (e.g., Malaysian sera)
and even when these populations were stratified based
on the strength of the VCA titer. More specifically, the
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higher the Ct for a particular miRNA, the lower the
observed VCA titer (Figure 7). In this regard, we
found that lowest NPC VCA titer group (IgG 40–160)
displayed the highest positive FC in EBV miRNAs
(FC 8–491) and the highest VCA titer group (>1280)
showed the lowest FC (0.39-1.02) (values < 1.0 considered a negative FC) (not shown).

Conclusions
Nasopharyngeal carcinoma (NPC) is a squamous cell
carcinoma of the head and neck, unique for its diverse
geographical clustering and its strong association with
Epstein Barr virus (EBV). Early detection of NPC is
difficult due the location of the tumor (deep in the
nasopharynx) and the lack of obvious clinical signs in
the early stages [57]. While there is an excellent response
to multimodal treatment (chemoradiation therapy) when
NPC is detected early, the prognosis after a late diagnosis
of NPC is dismal. Hence, there is an urgent need for an
accessible biomarker for the early detection of NPC. The
aberrant expression of miRNAs in carcinogenesis has
propelled these small non-coding RNAs to the forefront

Threshold cycle (Ct)

Threshold cycles of EBV miRNAs during qPCR
analysis of sera from different geographic locations

Figure 6 Box and whisker plots of EBV miRNA expression levels in sera determined using qPCR. Nine miRNAs were selected for qPCR
based on their overexpression in FFPE NPC tissue. Box and whisker plots of the threshold cycle (Ct) values are shown for all miRNAs according to
the geographical origin of the sera. MaC/MaN – Massachusetts control and test samples respectively (red); GC/GN – German control and test
samples respectively (purple); and MC/MN – Malaysian control and test samples respectively (green). Boxes encompass the range between the
upper and lower quartiles and whiskers extend to high/lowest values outside these bounds. Outliers, defined as greater/less than the upper/
lower quartile by more than 1.5 times the interquartile range, are plotted as points.
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Threshold cycle (Ct)

Threshold cycles of EBV miRNAs during qPCR analysis of Malaysian sera

Figure 7 Box and whisker plots of EBV miRNA expression levels in Malaysian sera determined using qPCR. Box and whisker plots of the
threshold cycle (Ct) values are shown for all miRNAs according to anti-viral capsid antigen (VCA) IgG titers. Low – IgG titers between 40–160;
Medium – IgG titers between 320–640; and High – IgG titers greater than 640. Boxes encompass the range between the upper and lower
quartiles and whiskers extend to high/lowest values outside these bounds. Outliers, defined as greater/less than the upper/lower quartile by more
than 1.5 times the interquartile range, are plotted as points. Significantly dysregulated miRNAs are highlighted with asterisks.

of recent cancer biomarker research [58]. One advantage
of miRNAs is their stability in biofluids, including sera,
plasma, urine, and saliva despite harsh conditions such as
high temperatures, extreme pH values, repeated freeze–
thaws, and long-term storage [59]. Moreover, miRNAs
generally survive intact in tissues that have been fixed in
formalin and embedded in paraffin (FFPE) for years [48].
With its extensive interaction with the host periphery,
we hypothesized that NPC primary tumors would
secrete miRNAs into the blood stream as shown for
other solid tumors (e.g., metastatic breast, colon, and
prostate cancers) [3]. Accordingly, we sought to test
different methods to identify signatures of miRNAs in
NPC FFPE tumor tissue versus non-neoplastic nasorespiratory control tissue and initiated this methods
testing by interrogating FFPE using two approaches.
The first approach was “targeted” method, where a
platform of known miRNAs were surveyed in FFPE
samples by microarray using miRBase 16. The second approach was “untargeted” method, where a high throughput analysis of all small RNA species in FFPE, including
yet to be discovered miRNAs, were identified by RNASeq. Using these two approaches similar miRNA profiles

were identified by microarray and RNA-Seq, with significantly dysregulated miRNAs then verified in both FFPE
and sera by qPCR.
With the exception of three miRNAs (−106b and -92a1/2), we found that miRNA expression levels in NPC
FFPE tissue were not necessarily reflected in miRNA
expression profiles in sera from NPC cases, though both
miRNAs expression profiles strongly associating with
NPC. Moreover, three of the overlapping miRNAs
found in both sera and tumor tissue were inversely
correlated (Figure 5A and 5C). Differing miRNA dysregulation profiles for tumor tissue and sera have been
described for other cancers, including breast cancer,
where several miRNAs have been shown to have an
inverse expression in the tumor compared to sera [60].
As such, we add to the literature on the methods for
measuring miRNAs yet another example of different
miRNA profiles in tissue and serum for the same
cancer, with both signatures strongly associated with
the malignancy. The finding of divergent expression
profiles in sera and tumor tissue is especially intriguing for NPC given the extensive interaction of this
solid tumor with the host [3]. Peripheral blood and
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saliva from NPC patients often contain tumor-derived
metabolites, including cytokines, non-cytokine tumor
proteins, and viral nucleic acids, as well as EBV antibodies and antigens [3].
Among the more persuasive hypotheses to explain the
divergent miRNA expression profiles between tissue and
sera is that the majority of human extracellular miRNAs
are encapsulated in microvesicles called ‘exosomes’ that can
be isolated from serum [61]. In particular, NPC-related
miRNAs, including EBV miRNAs, circulate in the plasma
within exosomes and play important roles in promoting
angiogenesis, cell proliferation, tumor-cell invasion and
immune evasion [3,6,62]. However, recent reports demonstrate the presence of the EBV miRNA BART17 in
plasma in the non-exosomal fraction [63]. Moreover,
miRNAs isolated from the non-exosomal fraction of
both plasma and sera have been found to be associated
with Argonaute 2, a key effector enzyme of miRNAmediated silencing [64]. Since the aim of our analysis
was to detect as many candidate miRNAs as possible in
sera, we isolated RNA from whole serum rather than
exosomes or exosome-depleted serum. Using this approach, we ensured that most of the exosomal and
non-exosomal miRNAs were available for detection
[61]. In addition, the RNA isolation protocol that we
used has been used by others to recover miRNAs, not
only from exosomal enriched serum fractions, but from
whole serum [65]. While the observed difference in the
presence of miRNAs between primary tissue and sera
cannot be explained by the sequestering of miRNAs in
exosomes, it could be that there is a selective secretion
of a particular set of miRNAs in exosomes derived from
the NPC cancer cell and/or cells present in the tumor
microenvironment.
A second objective of the study was to assess different
methods that could be utilized for biomarker discovery
of c-miRNAs for NPC. As such, we compared miRNA
expression profiles in FFPE by parallel technologies: a
‘targeted’ discovery method represented by microarrays,
where known miRNAs are surveyed by a release 16
human miRNAs (miRBase r16), and an ‘untargeted’
discovery method, where all miRNA copies present in
a sample (including unknown miRNAs) are surveyed by
small RNA sequencing on the Illumina platform. When
utilized in FFPE and sera, both platforms enabled us to
narrow the candidate miRNA signature to ~1-5% of the
known mature human miRNAs: e.g., RNA-Seq analysis
of FFPE and serum identified 99 and 20 dysregulated
miRNAs associated with NPC, respectively, from the
more than 2,200 human mature miRNAs in miRBase
Release 19.0. Hence, these platforms significantly reduced the number of ‘candidate’ miRNAs for an NPC
signature and allowed the use of a more cost effective
method (qPCR) to verify miRNAs in sera. Among the
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more important points that arose from our study of different miRNA discovers methods using different sample types is that due to the low abundance of miRNAs
in sera and the significantly lower average reads obtained by RNA-seq in sera samples versus FFPE samples (~1.5 million versus 3.5 million, respectively),
future studies should increase the sequencing depth
when sera is used as the sample matrix in order to detect low abundance miRNAs.
While successful prognostic miRNA profiling has been
demonstrated for NPC using targeted discovery platforms
(microarray) in FFPE [36], this study is the first to assess
available methods to identify NPC biomarkers using both
targeted and untargeted miRNA discovery technologies
on different sample types (Figure 1) [66]. We found
miRNA profiles were consistent between the two microarray (targeted) and RNA-Seq (untargeted) when these
two discovery technologies are applied to the same sample matrix: e.g. microarray versus RNA-Seq applied to
FFPE tissue. A benefit of the untargeted biomarker discovery technology (RNA-Seq) was the identification of
novel (i.e., unknown) miRNAs associated with NPC. Approximately 20 novel miRNA candidates were identified
in the study and are currently the objective of future
studies and verification by our group. These novel miRNAs may indeed prove valuable as potential biomarkers
for NPC, with further experimentation (including PCR
validation). However, as mentioned above, when the same
discovery technologies were applied to a different sample
matrices (serum), there was little overlap in dysregulated
miRNAs associated between the two NPC types, suggesting
that sera and tissue may have different miRNA profiles for
NPC. The absence of overlapping miRNAs between sera
and tissue as determined by both RNA-Seq and microarray
was verified by qPCR step.
Whereas RNA-Seq has been extensively utilized on FFPE,
much less information has been reported on RNA-Seq of
sera or plasma [19]. The average reads obtained per serum
sample for both serum and plasma as well as their mapping
are shown in Figure 3. From each individual serum sample,
we obtained ~1 million miRNA reads (~45% of the total
mapped reads). In FFPE samples, an average of > 2.5 million
miRNA reads per sample (>60% of total mapped reads)
were obtained. Other significant reads obtained from both
samples had no annotation, and a small percentage from
FFPE contained reads mapped to small nuclear RNA, protein coding, and other (long non-coding RNA, antisense
RNA, and vault RNA). Although both qPCR and RNA-Seq
of sera provided no significantly dysregulated EBV miRNAs, qPCR clearly detected the presence of EBV miRNAs
in NPC case compared to control sera. Conversely, the raw
copy counts for EBV miRNAs in RNA-Seq were low or
non-existent; suggesting that the sequencing depth obtained in RNA-Seq of sera was not sufficient to identify low
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abundance miRNAs. As mentioned previous, an important
result of this manuscript may be the need to increase the
depth of sequencing for miRNA when examining sera.
As an EBV associated malignancy, the expression of EBV
immunogenic proteins and antibodies in both tumor tissue
and blood were expected, and have been found to be indicative of an immune response against these carcinogenic
proteins [62]. Hence, we anticipated the occurrence of EBV
miRNAs in sera in similar patterns as found in previous
studies. For example, EBV derived miRNAs (such as BART
miRNAs) have been detected in the sera of NPC patients
and have been considered potential candidates for circulating NPC biomarkers [6,63]. Although 37 dysregulated EBV
miRNAs were identified in FFPE by RNA-Seq, we were
unable to discern a consistent and significant EBV miRNA
signature in the serum samples associated with NPC. Most
notably, there was a marked variability in miRNA levels
in sera across different geographic locations. Even when
limited to a single geographic location, such as sera from
Malaysia, wide variation was observed in EBV miRNA expression levels and significant differences between miRNA
in cases compared to controls could not be identified,
although some EBV miRNA expression levels did seem to
be inversely correlated with VCA titer.
In summary, this comparative analysis of the available
methods for the discovery of biomarkers in different
sample types revealed important information concerning
circulating miRNAs for NPC. First, it showed that optimized extraction protocols could produce sufficient
RNA from FFPE and sera for miRNA discovery and verification. Second, our study showed the marked reproducibility between the two different miRNA discovery
platforms when applied to FPPE, i.e., both targeted
(microarray) and untargeted (RNA-Seq) discovery platforms provided comparable miRNA expression profiles
when applied to FFPE tumor and healthy tissue controls,
although statistical methods for determining significance
provide different sets of significantly differentiated miRNAs. Third, c-miRNA expression profiles in the sera of
NPC cases differed from the miRNA expression profiles
in tumor FFPE, which may require future studies to increase the sequencing depth when sera is used as the
sample matrix in order to detect low abundance miRNAs. Finally, when there was an overlap of miRNAs
between FFPE and sera, the miRNAs tended to be inversely regulated. The latter two findings were unexpected given the assumption that biomarker discovery
should start from the primary tumor to develop candidate biomarkers which could be verified in the sera.
Finally, we concluded that the untargeted RNA-Seq approach applied to sera is the most informative method
for discovering circulating miRNAs associated with NPC
and possibly other cancers as well given its untargeted
nature.
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Additional files
Additional file 1: Representative images of non-keratinizing
nasopharyngeal carcinoma (NPC) [40] and non-neoplastic tissue.
Differentiated NPC (A) H&E (20X); (B) tumor cells with well-demarcated
cell borders and abundant cytoplasm, H&E (100X oil immersion).
Undifferentiated NPC [40]: (C) syncytial groups of tumor cells with
associated lymphocytes (short arrows) and plasma cells (arrowheads), H&E
(20X), (inset) in situ hybridization for EBV (EBER) positive in tumor cells;
(D) tumor cells with vesicular nuclear chromatin (long arrows) and
prominent nucleoli (arrowheads); mature lymphocytes (short arrows) are
present in the background, H&E (100Xoil immersion). Non-neoplastic
nasopharyngeal mucosa: (E,F) normal ciliated (arrow) nasorespiratory
surface epithelium, H&E (10x, 40X respectively).
Additional file 2: miRNAs and controls utilized on custom printed
PCR plates (SABiosciences) for verification in serum via qPCR. The
top 40 dysregulated miRNAs were selected based on the analysis of
microarray data from FFPE.
Additional file 3: miRNA expression profiles from eight samples by
Agilent microarray (miR release v. 16). Eight FFPE samples (four NPC,
four control) were analyzed using an unpaired t-test. miRNAs with
significant up or down regulations (fold change > 2.0 and p < 0.05) are
listed. Only miRNAs where ≥2 samples had raw values >20.0 are
presented.
Additional file 4: Scatter plot of miRNA qPCR findings from various
cDNA preparations of the same sample. Scatter plot of miRNA qPCR
findings from cDNA prepared from 30 ng total RNA (y-axis) and 250 ng
total RNA(x-axis) derived from FFPE (Panel A) and Caucasian sera
(Panel B). Diagonal lines indicate 2-fold threshold boundaries.
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